Wikidata

(Q39712673)

English

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

scientific article published on 20 April 2010

In more languages

Statements

title
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
author name string
Jonathan M Levitt
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
Hideyuki Yamashita
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
Weiguo Jian
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
Seth P Lerner
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
Guru Sonpavde
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
publication date
20 April 2010
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017
page(s)
1128-1135
1 reference
stated in
Europe PubMed Central
PubMed ID
20406945
retrieved
14 September 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q39712673&oldid=2089086628"